Key facts
- Universal DX’s last known valuation is $99.2M (Jan 2021).
- It has raised $144.0M; the latest was Later Stage VC in Jan 2026.
- Notable investors include MedTech Innovator, Endeavor Catalyst, Johnson & Johnson Innovation - JLABS, Spanish Society for Technological Transformation, Longbrook Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Universal DX
- ·The full record, as it builds
Funding rounds
No funding rounds for Universal DX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Universal DX
Operator of a bioinformatics and multi-omics company intended to transform cancer into a preventable and curable disease. The company combines proprietary tools with machine learning algorithms to offer minimally invasive, blood-based tests that can detect the disease in its earliest stages and forms, enabling doctors to have tools to achieve accuracy in early cancer detection.
- Sector
- Healthcare
- HQ
- Seville, Spain
- Founded
- 2012
- Employees
- 110
- Website
- universaldx.com/
- Ownership
- Privately Held (backing)
Universal DX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Universal DX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Universal DX in its N-PORT filings yet. We sweep new filings monthly.